

## Declaration of Interests Register

**Technology Appraisal Committee A**

**Publication Date: 17/02/2020**

**Topic: TA569 Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer [ID1192]**

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Dr Paul Robinson	Advisory Committee Member	<i>Transparency</i>	His company have launched a biosimilar to trastuzumab, which is not a comparator.		May 2018		Abstained from decision making. Agreed by: Dr Jane Adam, Chair Janet Robertson, Associate Director
Dr Alistair Ring	Clinical Expert	personal specific financial	Received honoraria for advisory boards from Roche and PUMA and for educational lectures from Roche.		May 2018		Declare and participate in the appraisal. Agreed by: Dr Jane Adam, Chair
Dr Alistair Ring	Clinical Expert	non-personal specific financial	His institution has received research funding from PUMA.		May 2018		Janet Robertson, Associate Director
Professor Andrew Wardley	Clinical Expert	direct financial	Has been paid by Roche for advisory work and speaker meetings. He is also the lead for development of a primary medical therapy trial in		July 2018		Declare and participate in the appraisal. Agreed by: Dr Jane Adam, Chair

			HER-2 positive breast cancer for NCRI breast cancer clinical studies group.				Janet Robertson, Associate Director
Melanie Sturtevant	Patient Expert	indirect	Her organisation receives funding from the pharmaceutical industry. This is independent of their work on access to drugs.		July 2018		Declare and participate in the appraisal. Agreed by:  Dr Jane Adam, Chair Janet Robertson, Associate Director

Link to Committee A interests register : <https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Technology-appraisal-committee/TAC-A-interests-register.pdf>

## GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

**Relevant dates:** Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.